However, the CD133+ fraction from both osteosarcoma cell lines were incapable of tumor formation when injected into non-obese diabetic (NOD)/severe combined immunodeficiency (SCID) mice which leads one to question the validity of CD133 expression in identifying a tumorigenic CSC population in osteosarcoma. This evidence concerns the gene PROM1 and neoplasm.